Virtual Monthly Seminars

Brought to you by the Members of the SFPM

A monthly series dedicated to showcasing advances in functional assays and their application in oncology precision medicine

Virtual Monthly Seminars

Come join us for our Virtual Monthly Seminar which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series should not be missed for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Next Seminar

Wednesday, May 8, 2024

@

12:00 PM EDT

UPDATED TIME - NOW 12 PM EASTERN TIME ZONE

Meeting URL: www.zoom.us
Meeting ID: 828 5622 5783
Passcode: 027718

Constantine Mitsiades
Constantine Mitsiades
Dana-Farber Cancer Institute
Systematic characterization of lineage-related dependencies with preferential roles in individual types of malignancies

Functional assays are in the truest sense precision medicine; matching a patient to a drug by directly testing their live tissue. The hypothesis is simple, yet in a personalized healthcare approach dominated by population scale genomics, the utilization of functional assays is limited. There exists a great opportunity to expand precision medicine beyond genomics, ultimately bringing better treatment options and the potential for greater outcomes to patients in need.

Bringing together a unique mix of pharmaceutical, academic and technology leaders, the series is must attend for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Through guest speakers, interactive panel discussions and Q&A sessions, the series will focus on these key topics:

The SFPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients and the treatments best suited for their cancer. This is possible through research, communication, and collaboration amongst our members and with outreach to the cancer therapy community as a whole. Become a Member today!

Members in good standing have access to our back catalog of seminar recordings.

Upcoming Speakers

June 12, 2024

Russell Jenkens, MD, PhD

Mass General Research Institute

July 12, 2024

Oliver Jonas

Harvard Medical School

September 11, 2024

Jared Barrott

Brigham Young University

September 11, 2024

Ken Dixon

SpeciCare

October 9, 2024

Kyuson Yun, PhD

Houston Methodist

November 13, 2024

Long-Sheng Lu

Taipei Medical Universtiy Hospital

December 11, 2024

Venu G. Pillarisetty, MD

Fred Hutch Cancer Center

Past Speakers

Bree Aldridge, PhD

Tufts University

Design of multidrug therapies for M. tuberculosis
Diana Azzam, PhD

Robert Stempel College of Public Health & Social Work

Clinical Utility of Functional Precision Medicine in the Management of Relapsed/Refractory Childhood Cancers
Santhosh Balasubramanian

Notable Labs

Designing precision oncology trials to develop and validate drug sensitivity assays
David A. Barbie, MD

Dana-Farber Cancer Institute

RNA Sequencing Analysis of Immunotherapy Response in Organotypic Tumor Spheroids
Patrick Bhola, PhD

Dana-Farber Cancer Institute

Rapid ex vivo testing using high content dynamic BH3 profiling may identify active therapies in solid tumors
Lawrence Boise, PhD

Emory University

Functional and phenotypic analysis of venetoclax sensitivity in multiple myeloma
Sara Cherry, PhD

University of Pennsylvania

Functional Precision Medicine in AML
Edward K. Chow, PhD

National University of Singapore

QPOP: Application towards Personalized Combinatorial Cancer Therapy
Jean-Philippe Coppé, PhD

UC San Francisco

Transformative kinase-activity mapping system to illuminate the phospho-catalytic dependencies and actionable vulnerabilities of therapy-resistant tumors
Kristine R. Crews, Pharm D., FCCP, BCPS

St. Jude Children's Research Hospital

Pharmacotype of Acute Lymphoblastic Leukemia, from Discovery to Implementation
Dr. Evan F. Cromwell

Protein Fluidics

Cancer Modeling, High-Content Imaging & Functional 3D Cell-Based Assays using novel Microfluidics Technology
Olivier Elemento

Weill Cornell Medicine

From reading genomes to patient avatars - the future of personalized medicine
Albert Folch, BSc, PhD

University of Washington

High-Throughput, High-Fidelity Cancer Drug Testing Using Intact Tumor Biopsies
Carla Grandori, MD, PhD

SEngine Precision Medicine

Real World Data on the Impact of Functional testing on Patient's Outcome for Solid Tumors: Wins and Challenges
Caroline Heckman, PhD

Institute for Molecular Medicine

Predicting drug combination efficacy in hematological malignancies by multi-parametric functional analysis
Sarah J. Hill, MD, PhD

Dana-Farber Cancer Institute

Studying the anti-tumor immune response in novel patient-derived high grade serous ovarian cancer organoid co-cultures
Peter J Houghton, PhD

UT Health, San Antonio

Single Mouse Testing (SMT) Approaches to Encompass Clinical Heterogeneity of Pediatric Cancers
Don Ingber, MD, PhD

Harvard University

Human Organ Chips for Disease Modeling, Drug Development, and Personalized Medicine
Dr. Lars Henrik Jensen

University Hospital Vejle, Denmark

Tumoroid-guidance in prospective interventional clinical trial in metastatic colorectal cancer (TICC)
Anand D. Jeyasekharan

National University Hospital of Singapore

Challenges and opportunities with clinical application of ex-vivo combination drug testing; lessons from lymphoma
Olli Kallioniemi

Karolinska Institute

Functional precision cancer medicine: molecular insights and clinical implementation in AML and beyond
Rich Klinghoffer, PhD

Presage

Intratumoral microdosing: Bridging the translational gap in cancer drug development and future potential as a functional diagnostic
Mika Kontro, MD, PhD

University of Helsinki

Predictive value of ex vivo sensitivity testing of venetoclax in AML
Razelle Kurzrock, MD

UC San Diego

Precision Medicine: Implementing N-of-1 combination therapies in the clinic
Heikki Kuusanmaki, PhD

University of Helsinki

Predictive value of ex vivo sensitivity testing of venetoclax in AML
Ines Lohse, PhD

University of Miami

Drug Sensitivity Testing for the Treatment Stratification of Cancer Patients
Scott Manalis, PhD

Massachusetts Institute of Technology

Single-cell mass as a clinical tool for guiding treatment decisions
Astrid Margossian, MD, PhD

SEngine Precision Medicine

Predictive Clinical Value of a CLIA-Approved Organoid Based Drug Sensitivity Test
Gordon Mills, MD, PhD

Oregon Health & Science University

Novel approaches to identifying and targeting adaptive responses in cancer: PARP inhibitors as an example.
Constantine Mitsiades

Dana-Farber Cancer Institute

Systematic characterization of lineage-related dependencies with preferential roles in individual types of malignancies
Joan Montero, PhD

University of Barcelona

Targeting the intrinsic pathway of apoptosis: an opportunity for functional precision medicine
Ina Oehme, PhD

Hopp Children’s Cancer Center Heidelberg and German Cancer Research Center

Drug sensitivity profiling of 3D tumor tissue cultures in the precision oncology programs MASTER & INFORM
Päivi Östling, PhD

SciLifeLab, Karolinska Institutet

New host targets for fighting SARS-Cov2 infection
Michael Pishvaian

Johns Hopkins University School of Medicine

Precision Medicine in Pancreatic Cancer
Vinayak Prasad, MD, MPH

University of California, San Francisco

The Limits of Genome Oncology
Christian Regnebrecht

ASC Oncology GmbH

Functional precision oncology beyond genomics: the future is already here but not evenly distributed
Clifford Reid

Travera, Inc.

A New Technology for Rapid Cancer Therapy Guidance
Analiz Rodriguez MD, PhD, FAANS

University of Arkansas Medical Sciences

Molecular Biobanking for Brain Tumor Precision Medicine
Julio Saez-Rodriquez, PhD

University of Heidelberg, Germany

Patient‐specific network models from screenings on biopsies for personalized medicine
Dr Ameen Salahudeen

Tempus Lab, Inc.

A pan-cancer organoid platform for precision medicine
Rosalie Sears, PhD

Oregon Health & Science University

Patient derived modeling to inform personalized therapeutics in pancreatic ductal adenocarcinoma
Jason Sicklick, MD, FACS

UC Sandiego Health

Moving from Drug-Centric to Patient-Centric Precision Oncology: Lessons Learned from the I-PREDICT Study
Sandy Simon

The Rockefeller University

Functional Precision Medicine for Effective Therapeutics for Cancer: Lessons from Fibrolamellar Hepatocellular Carcinoma
Sigrid Skanland

Oslo University Hospital

Functional precision medicine in chronic lymphocytic leukemia
Berend Snijder, PhD

ETH Zürich

Pharmacoscopy: real-time drug response testing for blood cancers and solid tumors.
Philipp Staber, MD PhD

Medical University of Vienna

Functional Precision Medicine for Patients with Hematologic Malignancies
Louis M. Staudt, MD, PhD

National Institues of Health

The Use of Targeted Agents to Cure Lymphoma: Precision Medicine to Achieve Effective Medicine for All
Gujral, PhD

Fred Hutchinson Cancer Research Center

Harnessing the Power of Polypharmacology to Uncover New Biology
Dr. Ole Thastrup

2cureX, Denmark

Tumoroid-guidance in prospective interventional clinical trial in metastatic colorectal cancer (TICC)
Hervé Tiriac, PhD

UCSD Moores Cancer Center

Pancreatic Cancer Patient-Derived Organoids as a Tool for Personalized Medicine
Gregory Vladimer, PhD, CSO

Allcyte

High content microscopy of primary patient material and AI in translational research and precision medicine
Alana L. Welm, PhD

Huntsman Cancer Institute

Functional precision medicine for metastatic breast cancer
Jun J. Yang, PhD

St. Jude Children's Research Hospital

Pharmacotype of Acute Lymphoblastic Leukemia, from Discovery to Implementation
Bruce Yeager

KIYATEC Inc

Positive, Negative or Neutral – What is current medical coverage policy landscape for Functional Precision Medicine (FPM) assays
Thorsten Zenz, MD

University of Zurich

Drug-perturbation-based stratification of blood cancer
Claudia R. Ball, PhD

National Center for Tumor Diseases Dresden and German Cancer Research Center

Drug sensitivity profiling of 3D tumor tissue cultures in the precision oncology programs MASTER & INFORM
Patricia Pérez-Galán, PhD

IDIBAPS - Hospital Clínic de Barcelona

Patient-derived non-Hodgkin lymphoma tumoroids: A tool to recapitulate tumor microenvironment, study disease biology and perform drug screening